Abstract: The present invention pertains to a stator manufacturing method and a device therefor. All of segments are twisted in order to obtain a stator, the linear sections of the segments being inserted into slots in a stator core. The segments on the inner peripheral side are subsequently twisted after the segments on the outer peripheral side are untwisted. In order to achieve this, e.g., a fourth spindle that is positioned on the outermost peripheral side and is one of the first through fourth spindles for twisting the segments is disconnected from a fourth motor and brought to a non-rotatable state. The following is then performed in sequence: the third spindle is disconnected from a third motor and twisted, and the second spindle is disconnected from the second motor and twisted.

Abstract: A stator manufacturing apparatus is equipped with spindles as twisting and bending jigs, an inner guide having a first supply flow path and a suction flow path formed in the interior thereof, and an outer guide having a second supply flow path formed in the interior thereof. Further, the spindles have receiving members in which insertion recesses are formed. Through holes are formed in the receiving members, and the receiving members are formed with lateral holes therein which allow the interiors of the insertion recesses to communicate with each other.

Abstract: The present invention pertains to a stator manufacturing method and a device therefor. All of segments are twisted in order to obtain a stator, the linear sections of the segments being inserted into slots in a stator core. The segments on the inner peripheral side are subsequently twisted after the segments on the outer peripheral side are untwisted. In order to achieve this, e.g., a fourth spindle that is positioned on the outermost peripheral side and is one of the first through fourth spindles for twisting the segments is disconnected from a fourth motor and brought to a non-rotatable state. The following is then performed in sequence: the third spindle is disconnected from a third motor and twisted, and the second spindle is disconnected from the second motor and twisted.

Abstract: Two cylinder heads are disposed side by side. Upper side intake valve holes of one of the cylinder heads and upper side exhaust valve holes of the other of the cylinder heads are simultaneously machined by a multi-spindle head integrally including intake side tools and exhaust side tools. After moving the one of the cylinder heads upward by a pitch of the intake valves and moving the other of the cylinder heads upward by a pitch of the exhaust valves, remaining intake valve holes of the one of the cylinder heads and remaining exhaust valve holes of the other of the cylinder heads are simultaneously machined.

Abstract: A stator manufacturing apparatus is equipped with spindles as twisting and bending jigs, an inner guide having a first supply flow path and a suction flow path formed in the interior thereof, and an outer guide having a second supply flow path formed in the interior thereof. Further, the spindles have receiving members in which insertion recesses are formed. Through holes are formed in the receiving members, and the receiving members are formed with lateral holes therein which allow the interiors of the insertion recesses to communicate with each other.

Abstract: Two cylinder heads are disposed side by side. Upper side intake valve holes of one of the cylinder heads and upper side exhaust valve holes of the other of the cylinder heads are simultaneously machined by a multi-spindle head integrally including intake side tools and exhaust side tools. After moving the one of the cylinder heads upward by a pitch of the intake valves and moving the other of the cylinder heads upward by a pitch of the exhaust valves, remaining intake valve holes of the one of the cylinder heads and remaining exhaust valve holes of the other of the cylinder heads are simultaneously machined.

Abstract: Two cylinder heads (3, 3) are disposed side by side. Upper side intake valve holes (34a, 34c, 34e, 34g) of one of the cylinder heads (3) and upper side exhaust valve holes (35a, 35c, 35e, 35g) of the other of the cylinder heads (3) are simultaneously machined by a multi-spindle head (24) integrally including intake side tools (26a to 26d) and exhaust side tools (28a to 28d). After moving the one of the cylinder heads (3) upward by a pitch P1 of the intake valves and moving the other of the cylinder heads (3) upward by a pitch P2 of the exhaust valves, remaining intake valve holes (34b, 34d, 34f, 34h) of the one of the cylinder heads (3) and remaining exhaust valve holes (35b, 35d, 35f, 35h) of the other of the cylinder heads (3) are simultaneously machined.

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C—F or the like; R1 represents a C1-C3 alkyl group; Y represents oxygen atom or N—R7; R2, R3, R4, R5, R6 and R7 each independently represents hydrogen atom, a C1-C6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C—X; X represents hydrogen atom or fluorine atom; R1 is hydrogen atom or a C1-C3 alkyl group; L represents single bond or a C1-C6 alkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; R2 represents hydrogen atom or a cyclic group which may be substituted, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A pyrimidone derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents hydrogen atom and Y represents hydroxyl group, or X represents fluorine atom and Y represents hydrogen atom; R1 represents a C1-6 alkyl group; R2 represents a morpholin-4-yl group which may be substituted, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: Two cylinder heads (3, 3) are disposed side by side. Upper side intake valve holes (34a, 34c, 34e, 34g) of one of the cylinder heads (3) and upper side exhaust valve holes (35a, 35c, 35e, 35g) of the other of the cylinder heads (3) are simultaneously machined by a multi-spindle head (24) integrally including intake side tools (26a to 26d) and exhaust side tools (28a to 28d). After moving the one of the cylinder heads (3) upward by a pitch P1 of the intake valves and moving the other of the cylinder heads (3) upward by a pitch P2 of the exhaust valves, remaining intake valve holes (34b, 34d, 34f, 34h) of the one of the cylinder heads (3) and remaining exhaust valve holes (35b, 35d, 35f, 35h) of the other of the cylinder heads (3) are simultaneously machined.

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A pyrimidone derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents hydrogen atom and Y represents hydroxyl group, or X represents fluorine atom and Y represents hydrogen atom; R1 represents a C1-6 alkyl group; R2 represents a morpholin-4-yl group which may be substituted, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C—X; X represents hydrogen atom or fluorine atom; R1 is hydrogen atom or a C1-C3 alkyl group; L represents single bond or a C1-C6 alkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; R2 represents hydrogen atom or a cyclic group which may be substituted, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C—F or the like; R1 represents a C1-C3 alkyl group; Y represents oxygen atom or N—R7; R2, R3, R4, R5, R6 and R7 each independently represents hydrogen atom, a C1-C6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A production method of an optically active 2-{4-(5-substituted-oxadiazolyl) phenyl}morpholine which is useful as an intermediate for synthesizing a pharmaceutical agent is provided and the method comprises the following steps 1) to 4): 1) reacting a bromophenylmorpholine with a hexacyanoferrate(II) or a hydrate thereof at a temperature of from 110° C. to 140° C. in a reaction mixture comprising a Na2CO3, an organophosphorus compound, and a palladium catalyst in a polar aprotic solvent alone or combination of a polar aprotic solvent and other polar aprotic solvent or hydrocarbon solvent to give a cyanophenylmorpholine; 2) reacting the cyanophenylmorpholine with hydroxylamine or hydroxylamine hydrochloride at a temperature of from 10° C. to 40° C.

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).